ERBB2 and breast carcinoma: The results showed that there was no statistical difference in RFS probability between the groups with high and low expression level of NT5E; however, the hazard ratio (HR) of the group with high expression of NT5E was >1, indicating that NT5E was a risk factor affecting the prognosis of HER2+ breast cancer patients (Figure 7H).